SCYX News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

SC

Mkt Cap

$36.2M

Volume

185.33K

Next Earnings

November 4th

Loading chart

SC

SCYXSCYNEXIS, Inc.

SCYX

Pay with—

Available Balance0.00

SC

Mkt Cap

$38.9M

Volume

185.33K

Next Earnings

November 4th

Chart Financials Earnings News About Insider Filings

Stock Market Today: S&P 500, Dow, Nasdaq Futures Up Amid US 'Defensive Strikes' On Iran— Elbit Systems, Intuitive Machines, Zscaler In Focus (UPDATED)U.S. stock futures rose on Tuesday following Memorial Day, with the S&P 500 and Nasdaq 100 gaining 0.52% and 0.73% respectively. Despite U.S. defensive strikes on Iranian missile sites, markets remained resilient as oil prices fell and Iran negotiations progressed. Key movers included Elbit Systems jumping 8.26% on a $1.4B military contract, Intuitive Machines soaring 10.27% on a NASA lunar contract, and SCYNEXIS plunging 16.38% after announcing a reverse stock split.Benzinga · May 26, 2026

SCYNEXIS Announces Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)SCYNEXIS, Inc. approved inducement equity awards for a new Vice President on April 30, 2026, consisting of stock options to purchase 125,000 shares at $0.93 per share and 20,000 restricted stock units. The awards were granted under the company's 2015 Inducement Award Plan in accordance with Nasdaq regulations.GlobeNewswire Inc. · May 7, 2026

SCYNEXIS Completes Transformative Acquisition of PXL-770, an innovative, highly selective, direct AMPK activator for the Treatment of Autosomal Dominant Polycystic Kidney Disease (ADPKD)SCYNEXIS announced the completion of its acquisition of PXL-770 (now SCY-770), a novel AMPK activator for treating ADPKD, the leading genetic cause of end-stage renal failure. Under the deal, SCYNEXIS will pay $8 million upfront with up to $188 million in potential milestone payments. The company plans to initiate a Phase 2 proof-of-concept study in Q4 2026 with early efficacy readout expected in H2 2027. SCY-770 has received FDA Orphan Drug Designation.Benzinga · Mar 31, 2026

SCYNEXIS Completes Transfer of BREXAFEMME® New Drug Application to GSKSCYNEXIS has transferred its BREXAFEMME New Drug Application to GSK, enabling potential regulatory interactions for relaunching the drug for vulvovaginal candidiasis. SCYNEXIS will receive potential net sales milestones and royalties from GSK.GlobeNewswire Inc. · Nov 19, 2025

Stay Ahead in Ophthalmology: Strategic Market Insights for Myopia Assessment & Forecasting | DelveInsightA leading company engaged DelveInsight to conduct a comprehensive study on the myopia market, including prevalence, treatment patterns, and market forecasts across the APAC region. DelveInsight's analysis provided strategic insights to help the client optimize its market entry and differentiation strategies.GlobeNewswire Inc. · Dec 20, 2024

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at IDWeek 2024SCYNEXIS, a biotechnology company, announced upcoming presentations of preclinical data on its second-generation antifungal compound SCY-247 at IDWeek 2024. SCY-247 is in pre-IND development and has shown broad-spectrum antifungal activity, including against multidrug-resistant pathogens.GlobeNewswire Inc. · Oct 3, 2024

SCYNEXIS Reports First Quarter 2024 Financial Results and Provides Corporate UpdateJERSEY CITY, N.J., May 08, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the first quarter ended March 31, 2024.GlobeNewswire Inc. · May 8, 2024

SCYNEXIS Presented Preclinical Data on Second Generation Fungerp SCY-247 at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global, Formerly ECCMID)JERSEY CITY, N.J., April 30, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second generation fungerp candidate SCY-247 at the ESCMID Global 2024 congress (formerly known as ECCMID) in Barcelona, Spain from April 27-30, 2024.GlobeNewswire Inc. · Apr 30, 2024

SCYNEXIS to Present Preclinical Data on Second Generation Fungerp SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID)JERSEY CITY, N.J., April 09, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today announced the presentation of preclinical efficacy data on its second-generation fungerp candidate SCY-247 at the 34th European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) in Barcelona, Spain from April 27-30, 2024.GlobeNewswire Inc. · Apr 9, 2024

SCYNEXIS Reports Full Year 2023 Financial Results and Provides Corporate UpdateJERSEY CITY, N.J., March 28, 2024 (GLOBE NEWSWIRE) -- SCYNEXIS, Inc. (NASDAQ: SCYX), a biotechnology company pioneering innovative medicines to overcome and prevent difficult-to-treat and drug-resistant infections, today reported financial results for the year ended December 31, 2023.GlobeNewswire Inc. · Mar 28, 2024

to start trading

SC

SCYXSCYNEXIS, Inc.

SCYX

Pay with—

Available Balance0.00

Your PositionYou don't own any SCYX yet.

Related Tickers

Earnings